GoldenGolden
Advanced Search
ATAI Life Sciences

ATAI Life Sciences

German life sciences company focused on psychedelic therapies for mental health conditions.

Overview

ATAI Life Sciences is a German biotech startup that creates, invests in, and acquires businesses developing psychedelic therapies with a focus on mental health. The company was founded in 2018 by Christian Angermayer, who serves as the company's chairman; Lars Wilde; Florian Brand, who serves as CEO; and Dr. Srinivas Rao, who serves as Chief Scientific Officer.

Programs

ATAI currently finances several companies conducting research on a wide range of mental health fields:

  • Treatment Resistant Depression
  • Cognitive Impairment associated with Schizophrenia
  • Opioid Use Disorder
  • Generalized Anxiety Disorder
  • Mild Traumatic Brain Injury
  • Post Traumatic Stress Disorder
Funding Rounds

ATAI completed a Series D funding round on March 3, 2021, raising $157M from a total of thirteen backers. Lead investors included Apeiron Investment Group, Thiel Capital,and Woodline Partners.

Timeline

March 3, 2021
ATAI Life Sciences raises a $157,000,000 series D round from Apeiron Investment Group, Thiel Capital and Woodline Partners.
November 24, 2020
ATAI Life Sciences raises a $93,000,000 series C round from Apeiron Investment Group and Catalio Capital Management.
March 28, 2019
ATAI Life Sciences raises a $43,000,000 series B round.
October 3, 2018
ATAI Life Sciences raises a $25,500,000 series A round from Recharge Capital.
June 7, 2018
ATAI Life Sciences raises a $3,600,000 seed round from Nimble Ventures.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Anna Cooban
May 30, 2021
Business Insider
DMT is the psychoactive agent found in Ayahuasca, a drink that has been prepared by Amazonian rainforest communities for thousands of years.
Yeji Jesse Lee
April 22, 2021
Business Insider
Atai wants to use ibogaine, ketamine, and other psychedelic compounds as treatments for mental-health conditions.
Emily Graffeo
April 22, 2021
markets.businessinsider.com
Atai Life Sciences, a company that aims to use psychedelic compounds for therapeutic uses, is planning to raise $100 million in an IPO.
Jeremy Berke and Yeji Jesse Lee
March 5, 2021
Business Insider
Welcome to Insider Cannabis, where we're bringing you an inside look at the deals, trends, and personalities driving the multibillion-dollar cannabis boom.
Freya Pratty
March 3, 2021
Sifted
Berlin-headquartered biotech firm Atai Life Sciences has raised $157m amid the global race to commercialise psychedelics.
Annabelle Williams
March 3, 2021
Business Insider
Atai Life Sciences recently raised $157 million in its Series D funding round, and reports say its looking at a possible public listing.
Yeji Jesse Lee
March 3, 2021
Business Insider
CEO Florian Brand told Insider that the money will be used to "double down" on the company's existing strategy.
Sian Bradley
March 1, 2021
Sifted
European companies like Compass Pathways, Berkley Psytech and Atai Life Sciences are leading the race to dominate the new psychedelics market.
Dr. Catherine Schuster-Bruce
December 17, 2020
Business Insider
There's a new UK venture fund, Neo Kuma, dedicated to psychedelics. Cofounder Clara Burtenshaw sets out her strategy for the emerging and risky field.
Amirah Al Idrus
November 23, 2020
FierceBiotech
ATAI Life Sciences is topping off a busy year with a $125 million financing, which will support the preclinical and clinical development for its mental health pipeline, including programs in opioid use disorder and depression. The series C round follows a $43 million round in March 2019.
Freya Pratty
November 23, 2020
Sifted
Atai Life Sciences has secured $125m in funding to develop drugs for mental health treatment, including ketamine, MDMA and psilocybin.
Jeremy Berke and Yeji Jesse Lee
November 23, 2020
Business Insider
The mental health fallout from the coronavirus pandemic may have increased investor interest in the round, CEO Florian Brand said.
Michael Stothard
November 16, 2020
Sifted
Christian Angermayer has been one of the investors most resonsible for the global psychedelic renaissance with Compass Pathways and Atai Life Sciences.
Krystle Vermes
August 25, 2020
BioSpace
ATAI Life Sciences announced on Monday that it has launched EmpathBio, a wholly-owned subsidiary focused on developing derivatives of 3,4-methylenedioxy-methamphetamine (MDMA) for the treatment of post-traumatic stress disorder.
BioSpace
July 22, 2020
BioSpace
Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for a variety of mental health indications, announced the launch of Viridia Life Sciences, a wholly-owned subsidiary developing novel formulations of N,N-Dimethyltryptamine (DMT) to treat a variety of mental health disorders.
BioSpace
June 22, 2020
BioSpace
Today, ATAI Life Sciences ("ATAI" or the "Company"), a global biotech developing psychedelic and non-psychedelic compounds for various mental health indications, announced the launch of its digital therapeutic platform IntroSpect Digital Therapeutics, Inc. ("IntroSpect").
Amirah Al Idrus
June 22, 2020
FierceBiotech
ATAI Life Sciences aims to transform mental health care, backing companies working on new treatments for depression, anxiety and addiction. Now, it's adding digital tools to the mix through a new company called IntroSpect Digital Therapeutics. IntroSpect will create digital tools and devices that will "magnify" the effects of drugs in development at ATAI's companies.
Denise Paglinawan
November 18, 2019
BetaKit
Toronto-based biotechnology company Cyclica has partnered with global biotechnology platform ATAI Life Sciences to develop drugs for mental health disorders.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.